Document Detail


Low-dose ethinylestradiol/levonorgestrel.
MedLine Citation:
PMID:  16266199     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Low-dose ethinylestradiol/levonorgestrel 20 microg/100 microg is a combined oral contraceptive that prevents pregnancy primarily by inhibiting ovulation. The Pearl index (pregnancies per 100 woman-years of use) with ethinylestradiol/levonorgestrel 20 microg/100 microg was 0.88 and the cumulative pregnancy rate was 1.9% at the end of a 3-year open-label trial (1708 women with 26 554 evaluable cycles). The contraceptive efficacy of ethinylestradiol/levonorgestrel 20 microg/100 microg was similar to that of other low-dose combined oral contraceptives containing ethinylestradiol 20 or 35 microg in a 6-cycle trial (463 evaluable women). Ethinylestradiol/levonorgestrel 20 microg/100 microg is well tolerated; adverse events were those commonly associated with combined oral contraceptives. Headache and metrorrhagia (2% of women) were the most common adverse events leading to treatment discontinuation in the 3-year trial. Cycle control in open-label trials in women receiving up to 36 cycles of ethinylestradiol/levonorgestrel 20 microg/100 microg was generally good, with the incidence of intermenstrual bleeding being highest during the first few cycles of use and decreasing thereafter.
Authors:
Toni M Dando; Monique P Curran
Related Documents :
1879389 - Effects of reviewing risk-relevant behavior on perceived vulnerability among women mari...
7357869 - The effect of the intrauterine contraceptive device on the prevalence of morphologic ab...
10693729 - Postfertilization effects of oral contraceptives and their relationship to informed con...
18480499 - Treating humanity as an inviolable end: an analysis of contraception and altered nuclea...
12618259 - Safety and acceptability of post-abortal iud insertion and the importance of counseling.
6413129 - Why do inadvertent pregnancies occur in oral contraceptive users? effectiveness of oral...
1595959 - Ultrasonographic appearance of the uterus, placenta, fetus, and fetal membranes through...
11750959 - The perinatal outcome of pregnancy without prenatal care. a retrospective study in szeg...
2455429 - Serum levels of estrogens and of five 'steroid sensitive' proteins in early normal preg...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  65     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2005  
Date Detail:
Created Date:  2005-11-03     Completed Date:  2006-02-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  2299-306; discusion 2307-8     Citation Subset:  IM    
Affiliation:
Adis International Limited, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Contraceptives, Oral, Combined / administration & dosage,  adverse effects,  therapeutic use*
Ethinyl Estradiol / administration & dosage,  adverse effects,  therapeutic use*
Female
Humans
Levonorgestrel / administration & dosage,  adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Contraceptives, Oral, Combined; 57-63-6/Ethinyl Estradiol; 797-63-7/Levonorgestrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Docetaxel in hormone-refractory metastatic prostate cancer.
Next Document:  Atazanavir: a review of its use in the management of HIV infection.